

Comprehensive Analysis of Therapeutic Strategies Using Mesenchymal Stem Cell-Derived Exosomes in Preclinical Models of Osteoarthritis

Riya Mukherjee¹, Ramendra Pati Pandey²⁺, Gunjan¹, Himanshu¹, Ing-Kae Wang³, Sing-Ying Hsieh³, Chung-Ming Chang^{1,4,5*}

¹Graduate Institute of Biomedical Sciences, Chang Gung University; riya.mukherjee1896@gmail.com (R.M.).

²School of Health Sciences and Technology (SoHST), UPES Dehradun, Uttarakhand, India ramendra.pandey@gmail.com (R.P.P.); ramendra.pandey@ddn.upes.ac.in

³Cell Culture Medium Technology Development, Regeneration Medicine Technology Division, Biomedical Technology and Device Research Laboratories, ITRI, Chutung, Hsinchu, Taiwan 310401, R.O.C.

⁴Master & Ph.D Program in Biotechnology Industry, Chang Gung University; cmchang@mail.cgu.edu.tw (C.M.C.).

⁵Department of Medical Biotechnology and Laboratory Science; Chang Gung University cmchang@mail.cgu.edu.tw (C.M.C.).

++Contributed equally as first authorship

****Corresponding author**

Chung-Ming Chang*, Master & Ph.D. program in Biotechnology Industry, Chang Gung University, No.259, Wenhua 1st Rd., Guishan Dist. Taoyuan City 33302, Taiwan (R.O.C.), cmchang@mail.cgu.edu.tw (C.M.C.).

Abstract

Background

Osteoarthritis (OA) is a common degenerative disease affecting people and animals, resulting in persistent pain and joint deformities. Its growing prevalence presents considerable difficulties to public health and veterinary care systems worldwide. Despite substantial research, the molecular pathways underlying OA pathogenesis remain poorly understood, limiting the development of effective treatment strategies. Exosomes, or small endosomal membrane microvesicles, have emerged as intriguing vehicles for intercellular communication and medicinal administration in a variety of illnesses, including OA. However, their efficacy and action methods in preclinical OA models require additional exploration.

Methods

We analyzed several databases from 2016 to 2023 for original studies on exosome treatment in preclinical OA models. The inclusion criteria included studies that used exosomes generated from mesenchymal stem cells (MSCs) in both human and animal models of OA. Thematic synthesis and data extraction were used to examine research features, dosage administration techniques, and efficacy results. The quality of included studies was assessed using recognized

40 criteria, and statistical analysis was performed to determine the efficacy of exosome treatment in
41 decreasing Osteoarthritis Research Society International (OARSI) scores.

42

43 **Results**


44 Our study comprised thirteen peer-reviewed articles that included both human and animal
45 models of OA. Most trials used bone marrow MSC-derived exosomes administered intra-
46 articularly. The analysis of OARSI scores revealed a considerable reduction in joint deterioration
47 following exosome therapy. Source analysis demonstrated that exosome treatment originating
48 from human and animal MSCs was consistently effective. However, an assessment of study
49 quality revealed potential biases and limitations, emphasizing the need for more research to
50 validate these findings and refine therapy options for OA management.

51

52 **Keywords**

53 Osteoarthritis, Exosome Therapy, Mesenchymal Stem Cells, Preclinical Studies, Therapeutic
54 Efficacy.

55 **Graphical Abstract**



56

57

58 **1. Introduction**

59 Osteoarthritis (OA) is the most common degenerative disease both in humans and in animals, a
60 leading cause of disability, and is characterized by chronic pain and a range of joint
61 abnormalities, including articular cartilage damage, synovial inflammation, subchondral bone
62 remodeling, and the formation of osteophytes (Steinmetz et al., 2023; Tong et al., 2022). The
63 incidence of OA is steadily increasing due to the rising aging population and the global obesity
64 epidemic, imposing a significant socioeconomic burden and posing a significant challenge to
65 public health (A. R. Sun et al., 2021; Wen & Xiao, 2022; X. Wu et al., 2022). The World Health
66 Organization (WHO) has designated the period from 2021 to 2030 as the "Decade of Healthy
67 Ageing," with a particular emphasis on enhancing both life expectancy and overall quality of
68 life. This designation presents an important opportunity to address the burden of OA within the
69 framework of adult health (WHO). Due to the chronic nature of osteoarthritis and its substantial
70 impact on mobility and daily functioning, this is especially important. According to a WHO
71 report, in 2019, approximately 528 million people worldwide were living with OA, marking a
72 113% increase since 1990. Most individuals affected by OA, about 73%, were aged 55 and older,
73 with females accounting for 60% of the total. With 365 million incidents, the knee emerged as
74 the most affected joint, followed by the hip and the hand (WHO, 2023). A population-based
75 meta-analysis published in a Chinese publication in 2019 combined existing papers to determine
76 the prevalence of knee joint osteoarthritis (OA) in China. The investigation found that the
77 prevalence of knee joint OA in China stood at 17%, with a breakdown of 12.3% in men and
78 22.2% in women (X. Sun et al., 2019). In a separate study conducted in 2019, which compiled
79 and analyzed existing publications, the research identified lumbar joint OA as the most
80 widespread type of OA. It exhibited a prevalence rate of 25.03% in Chinese middle-aged and
81 elderly populations. Knee joint OA came in second with a prevalence of 21.51%, followed by
82 cervical joint OA at 20.46%, and hand joint OA at 8.99% (X. Sun et al., 2019). Additionally, in
83 Taiwan, knee OA has a prevalence rate of approximately 15%, impacting more than 3.5 million
84 individuals who experience joint pain (DuoGenicStemCellscorporation, 2023). Furthermore, In
85 India, from 1990, OA, number rose from approximately 23.46 million people to 62.35 million by
86 2019 (Singh et al., 2022). According to the CDC, 32.5 million US individuals have OA, and 1 in
87 4 (or 54.4 million) US adults have some form of arthritis. By the year 2040, 78 million people
88 will be predicted to have arthritis worldwide (Alliance). In Western Europe, OA affected
89 approximately 57 million people in 2019 and cost over 2 million years of healthy life. Since
90 1990, the number of people affected in the area has increased by 54% (Economist, 2019).
91 Besides, in US, 63.4 million households have a dog, and there are an estimated 9 million pet
92 dogs owned there (PFMA, 2018), Osteoarthritis affects many dogs globally and is a danger to the
93 wellbeing of dogs. According to information gathered from 200 veterinarians, 20% of all dogs in
94 North America over the age of one are estimated to have osteoarthritis (SA, 1997). Recent
95 estimates suggest that osteoarthritis affects 2.5% to 6.6% of dogs of all ages and breeds visiting
96 primary care offices in the United Kingdom (Pye et al., 2024). Canine osteoarthritis is a
97 significant concern for veterinarians, owners, and breeders worldwide, and it has a considerable

98 impact on the welfare of dogs. The financial burden of treatment options for canine osteoarthritis
99 can be particularly challenging for dog owners.

100 At the molecular level, the pathogenesis of OA involves complex interactions between various
101 cellular and molecular processes. These include dysregulation of chondrocyte metabolism,
102 abnormal remodeling of the extracellular matrix, activation of inflammatory pathways, and
103 disruption of homeostatic mechanisms. Despite decades of research, the exact causes and
104 molecular mechanisms underlying OA are not fully understood, which contributes to the limited
105 effectiveness of traditional therapeutic approaches in stopping the progression of the disease
106 (Tong et al., n.d.). Chondrocytes, the cells responsible for maintaining cartilage integrity, play a
107 central role in the pathogenesis of OA. Dysregulated chondrocyte metabolism leads to
108 imbalances in extracellular matrix (ECM) turnover, characterized by decreased synthesis of
109 collagen and proteoglycans, and increased expression of matrix metalloproteinases (MMPs) and
110 aggrecanases. These enzymes degrade the ECM, compromising cartilage structure and function.
111 Synovial inflammation is a defining feature of osteoarthritis and contributes to its development.
112 OA joints exhibit higher levels of inflammatory mediators, including IL-1 β , TNF- α , and PGE2.
113 These cytokines enhance chondrocyte catabolism, accelerate cartilage breakdown, and drive
114 synovial cell production of inflammatory mediators. In OA, dysregulated signaling pathways
115 such NF- κ B, MAPK, and Wnt/ β -catenin contribute to inflammation, apoptosis, and ECM
116 degradation. The activation of these pathways results in the expression of pro-inflammatory
117 cytokines, catabolic enzymes, and cartilage breakdown mediators (Yao et al., n.d.).

118 Exosomes are small endosomal membrane microvesicles that have gotten a lot of interest in the
119 last decade. Exosomes were discovered in extracellular space as early as the late 1980s (Y.
120 Zhang, Liu, Liu, & Tang, 2019). Exosomes released by cells, on the other hand, were previously
121 proposed as cellular waste resulting from cell injury or by-products of cell homeostasis, with no
122 substantial impact on nearby cells (Y. Zhang et al., 2019). It was only recently that these
123 extracellular vesicles were shown to be functional vehicles capable of conveying a complex
124 cargo of proteins, lipids, and nucleic acids to the target cells they encountered, which may
125 eventually reprogram the destination cells distal from their release (S.-p. Li, Lin, Jiang, & Yu,
126 2018). Thus, exosomes constitute a novel route of intercellular communication that may be
127 important in a variety of cellular activities, including immunological response (Greening, Gopal,
128 Xu, Simpson, & Chen, 2015), signal transduction (Gangoda, Boukouris, Liem, Kalra, &
129 Mathivanan, 2015), and antigen presentation (Smith, Cheng, Bryant, & Schorey, 2017).
130 Exosomes can be discharged by almost all eukaryotic cells, and their cargos are thought to differ
131 substantially depending on the origin of the cell type and its current condition (e.g. transformed,
132 differentiated, stimulated, and stressed). Thus, exosomes and their biologically active cargos may
133 provide preemptive information in a variety of disorders, including neurodegenerative, and
134 degenerative diseases (Howitt & Hill, 2016; W. Liu et al., 2019). Emerging studies
135 demonstrated that, exosomes originating from mesenchymal stem cells (MSCs) provide
136 protective effects for bone and cartilage in OA (Zhu et al., 2017). They achieve this by elevating

137 the expression of chondrocyte markers such as type II collagen and aggrecan, suppressing
138 inflammatory markers like nitric oxide synthase (iNOS), preventing chondrocyte apoptosis, and
139 promoting both the migration and proliferation of chondrocytes (Zhu et al., 2017) and inhibiting
140 the activation of macrophages (Cosenza, Ruiz, Toupet, Jorgensen, & Noël, 2017). Consequently,
141 exosomes are believed to have a role in the development and progression of various diseases,
142 including OA.

143 In the field of clinical practice, systematic reviews and meta-analyses, conducted with strict
144 adherence to scientific standards, are considered the most objective and comprehensive methods
145 for evaluating intervention effectiveness. To ensure the validity of our findings, we conducted a
146 thorough analysis of the efficacy and likely mechanisms of exosome utilization in both human
147 and animal pre-clinical models of osteoarthritis. Our study focused uniquely on osteoarthritis
148 among the various degenerative diseases. We believe that this analysis of preclinical data will
149 significantly contribute to shaping the design of future clinical trials. The efficacy of exosomes
150 in preclinical settings presents intriguing opportunities for future research in the veterinary and
151 public health fields.

152 **2. Materials and methods**

153 *2.1. Data Collection*

154 An extensive literature search was conducted from 2016 to 2023 by utilizing various databases,
155 including Web of Science, Google Scholar, ScienceDirect, PubMed, ProQuest, EMBASE, and
156 SCOPUS. The aim was to carry out a comprehensive analysis focused on the topics of
157 'extracellular vesicles' or 'exosomes' and their relevance to 'osteoarthritis'. To construct our
158 search strategy, we employed a combination of Medical Subject Headings (MeSH) terms, free-
159 text keywords, and Boolean operators (AND or OR). The search strategy can be outlined as
160 follows with the following keywords: (exosome OR microvesicles OR exosomes OR
161 extracellular vesicles) AND (human OR (animal OR mouse OR rat OR rabbit)) AND (arthritis or
162 osteoarthritis OR degenerative joint disease OR Degenerative arthritis OR degenerative joint
163 disease OR Knee osteoarthritis). This search strategy was applied across different Medline
164 databases. The design and reporting of this study adhered to the guidelines outlined in the
165 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement
166 (Liberati, Altman, Tetzlaff, & Mulrow, 2009; A. Liberati et al., 2009).

167 *2.2. Inclusion and exclusion criteria*

168 Based on the specified inclusion and exclusion criteria below, a total of 13 papers were selected
169 for retrieving information. Studies were included in the analysis if they met the following
170 criteria: (i) original investigation in humans' and animals' pre-clinical models with osteoarthritis,
171 (ii) exosome-based therapy, (iii) studies including author names, publication year, weight,
172 number of dosages, dosage units, and route of administration. Articles undergoing full-text were
173 excluded for the following reasons: (i) being review articles, (ii) inability to extract or obtain data

174 from the original authors, (iii) incomplete data or data expressed as ratios or percentages, and
175 (iv) not being published as a full-text article in a journal.

176 *2.3. Data extraction*

177 Data from various osteoarthritis (OA) treatments using exosomes were systematically compiled
178 into a spreadsheet using Excel® (Microsoft® Office Excel 2013) and subjected to preliminary
179 testing before complete extraction. The extracted information included the author's name,
180 country of publication, year of publication (2017–2023), mesenchymal stem cell source, isolation
181 method, exosome size, tissue origin, exosome immunocompatibility, and associated degenerative
182 disease. Additionally, another spreadsheet was created to include author's name, dosage
183 administration, route of application, number of dosages, age, weight, and OARSI scores. The
184 collected data were analyzed further, and details related to OA treatment strategies were
185 meticulously organized into tables. Citations from the compiled papers were managed using
186 Endnote 20 (Clarivate Analytics, U.S.A).

187 *2.4. Quality assessment*

188 Assessment of the reporting quality of included studies was performed using a scoring system
189 adapted from (Papazova et al., 2015; Wever et al., 2012). Evaluating publication bias is essential
190 to ensure the integrity and validity of our meta-analysis in assessing the effects of exosomes on
191 osteoarthritis (OA). Our approach aimed to systematically address any potential bias, ensuring
192 that our meta-analysis offers an impartial synthesis of the existing evidence on the therapeutic
193 benefits of exosomes in OA. Furthermore, we employed a risk bias checklist across multiple
194 domains (D1 to D5), with each domain evaluated using five categories: high risk, some concerns,
195 low risk, no information, and not applicable. Evaluation of the risk of bias was performed using
196 version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) (Sterne JAC, 2019).

197 *2.5. Statistical analysis*


198 The statistical analysis and generation of forest plots and heat maps for pooled summary
199 estimates were conducted using the meta or metaphor and stats package in R software. The
200 summary estimates were derived from pooled data of forest plots representing Osteoarthritis
201 Research Society International (OARSI) scores in the OA model of humans and animals before
202 and after exosome treatment. 95% confidence intervals (CI) and odds ratios (OR) for both fixed-
203 effect and random-effects models were calculated. OARSI is a widely used indicator of success
204 in research on osteoarthritis. It was created by international specialists in the field working in
205 consensus, and it has been approved for use in clinical trials. Making use of a standardized
206 outcome measure, such as the OARSI, can assist assure consistency between research and enable
207 useful comparisons. Utilizing OARSI can also make it easier to combine data from several
208 research, improving the meta-analysis's statistical power and accuracy. The I^2 and τ^2 statistics
209 were used to evaluate the heterogeneity of the data. Random-effect models were employed for all

210 meta-analyses, and the outcomes were presented in forest plots. Additionally, the statistical
211 significance was determined by p-value ($p \leq 0.05$).

212 3. Results

213 3.1. Study Selection

214 A total of 1280 papers published between 2016 and 2023 were systematically categorized using
215 Medline databases i.e. PubMed, Google Scholar, Scopus, and ISI Web of Science. Following a
216 preliminary assessment of titles and abstracts, 326 studies underwent initial screening. From
217 these, 247 records were excluded due to irrelevance or redundancy, leaving 79 articles for further
218 examination. Subsequently, 59 articles were excluded for various reasons: 10 articles were
219 excluded for improper screening, 9 articles due to no relevant animal intervention, 32 articles
220 were review articles, 2 were case studies, 2 were book chapters, and 4 articles could not be
221 accessed Further proper screening process include 20 studies. Among these, 7 articles were
222 excluded for the following reasons: in 5 articles, exosomes were not derived from mesenchymal
223 stem cells, and 2 articles had incomplete data. Finally, 13 studies (Cosenza et al., 2017; He et al.,
224 2020; Jin et al., 2021; X. Li et al., 2021; Liang et al., 2022; Lin et al., 2021; Y. Liu et al., 2022;
225 Tao et al., 2017; Wang et al., 2021; J. Wu et al., 2019; J. Zhang, Rong, Luo, & Cui, 2020; Zhu et
226 al., 2017). were selected for this meta-analysis. The study selection process adhered to the



227 PRISMA flow diagram (A. Liberati et al., 2009), depicted in Figure 1.

228 **Figure 1.** PRISMA chart depicting the inclusion criteria for studies investigating exosome
229 therapy in preclinical models of osteoarthritis.

230 3.2. Study Characteristics

231 The study summarizes data from various studies on the use of exosomes derived from human
232 mesenchymal stem cells (MSCs) for osteoarthritis (OA) treatment, spanning from 2017 to 2022
233 (**Table 1**). Most studies are from China and focus on human-derived MSCs. A common aspect
234 among the studies is the use of ultracentrifugation as the primary method for exosome isolation,
235 seen in the works of Zhu et al. (2017), Lin et al. (2020), Jin et al. (2021), Liu et al. (2022), Wang
236 et al. (2021), Tao et al. (2017), and Li et al. (2022). Other methods include tangential flow
237 filtration (Zhang et al., 2019) and the exoEasy Kit (Yang et al., 2022). The exosome sizes
238 reported range from 30 to 200 nm. The sources of MSCs vary, including induced pluripotent
239 stem cells (ipMSC), synovial membrane MSCs (SMMSC), dental pulp stem cells (DpSCs), bone
240 marrow (BM), knee articular cartilage, human synovial tissue, embryonic stem cells, and
241 umbilical cord (UC) MSCs.

242 In terms of immunocompatibility, most exosomes are characterized as xenogenic, except for
243 Liang et al. (2022), who reported allogenic exosomes. The studies uniformly target OA as the
244 degenerative disease of interest. Despite variations in exosome sizes and specific MSC sources,
245 the overarching goal remains the same: exploring the therapeutic potential of MSC-derived
246 exosomes in OA treatment. The detailed scrutiny and organization of these studies into tables
247 enable a comprehensive understanding of OA treatment strategies using exosomes, as well as the
248 methodologies and outcomes associated with each study.

249 **Table 1.** Interventional data of exosomes derived from human sources.

Publication Year	Author's Name	Country	Size	Isolation Techniques	Source of MSCs	Tissue Origin	Exosome Immunocompatibility	Degenerative Disease	Ref.
2017	Zhu. <i>et.al</i>	China	30-150nm	Ultracentrifugation	Human	ipMSC ¹ & SMMSC ²	Xenogenic	OA	(Zhu et al., 2017)
2020	Lin. <i>et.al</i>	China	134±29nm	Ultracentrifugation	Human	DpSCs ³	Xenogenic	OA	(Lin et al., 2021)
2021	Jin. <i>et.al</i>	China	50-150nm	Ultracentrifugation	Human	BM ⁴	Xenogenic	OA	(Jin et al., 2021)

Abbreviations

¹ ipMSC : Induced pluripotent MSCs

² SMMSC: synovial membrane MSCs

³ DpSCs: Dental pulp stem cells

⁴ BM: Bone Marrow

2022	Liu. <i>et.al</i>	China	135.5nm	Ultracentrifugation	Human	HuSMC ⁵	Xenogenic	OA	(Y. Liu et al., 2022)
2021	Wang. <i>et.al</i>	China	100-120nm	Ultracentrifugation	Human	Knee articular cartilage	Xenogenic	OA	(Wang et al., 2021)
2017	Tao. <i>et.al</i>	China	30-150nm	Ultracentrifugation	Human	Human synovial	Xenogenic	OA	(Tao et al., 2017)
2019	Zhang. <i>et.al</i>	Singapore	100-200nm	Tangential Flow Filtration	Human	Embryonic stem cell	Xenogenic	OA	(Zhang. <i>et.al</i> , 2019)
2022	Li. <i>et.al</i>	China	30-200nm	Ultracentrifugation	Human	UC ⁶	Not specified	OA	(Li. <i>et.al</i> , 2022)
2022	Yang. <i>et.al</i>	China	131.2nm	exoEasy Kit	Human	BM	Not specified	OA	(Yang. <i>et.al</i> , 2022)
2022	Liang. <i>et.al</i>	China	150-190nm	Centrifugation	Human	BM	Allogenic	OA	(Liang et al., 2022)

250

251 Table 2, summarizes interventional data from studies on exosomes derived from animal sources
 252 for osteoarthritis (OA) treatment, spanning from 2017 to 2020 and involving researchers from
 253 France and China. Common across these studies is the use of centrifugation for exosome
 254 isolation, with Cosenza et al. (2017) and He et al. (2020) using standard centrifugation, and
 255 Zhang et al. (2020) employing ultracentrifugation. The MSCs were sourced from rodents,
 256 specifically mice (Cosenza et al., 2017) and rats (He et al., 2020; Zhang et al., 2020), with bone
 257 marrow (BM) being the primary tissue origin. Exosome sizes ranged from 96 nm to 153 nm, and
 258 all exosomes were allogenic, indicating derivation from the same species but different genetic
 259 backgrounds. Each study uniformly focused on OA, highlighting a shared interest in the
 260 therapeutic potential of animal-derived MSC exosomes for this condition. The table's detailed
 261 organization facilitates a comprehensive understanding of OA treatment strategies using these
 262 exosomes.

263 **Table 2.** Interventional data of exosomes derived from animal sources.

Publication Year	Author's Name	Country	Size (nm)	Isolation Techniques	Source of MSCs	Tissue Origin	Exosome Immunocompatibility	Degenerative Disease	Ref
2017	Cosenza. <i>et.al</i>	France	96	Centrifugation	Mouse	MBM ⁷	Allogenic	Osteoarthritis	(Cosenza et al., 2017)
2020	He. <i>et.al</i>	China	153	Centrifugation	Rat	BM	Allogenic	Osteoarthritis	(He et al., 2020)

⁵ **HuSMC:** Human urine-derived stem cells

⁶ **UC:** Umbilical Cord

⁷ **MBM:** Murine Bone Marrow

2020	Zhang. <i>et.al</i>	China	140	Ultracentrifug ation	Rat	BM	Allogenic	Osteoarthritis	(J. Zhang et al., 2020)
------	------------------------	-------	-----	-------------------------	-----	----	-----------	----------------	----------------------------

264

265 3.3. Dosage Administration

266 The studies investigating the therapeutic efficacy of mesenchymal stem cell-derived exosomes in
 267 preclinical models of osteoarthritis (OA). Each study is characterized by specific parameters,
 268 including dosage, administration route, number of dosages, age and weight of the animal models,
 269 and the Osteoarthritis Research Society International (OARSI) scores before and after exosome
 270 treatment (**Table 3**). Notably, the studies emphasize the use of exosomes derived from human
 271 sources, highlighting their potential therapeutic importance. Zhu et al. (2017) administered 8 μ l
 272 of human-derived exosomes at a concentration of 1.0×10^{10} /ml via intra-articular injections,
 273 with two doses given to 6-week-old animals. The primary outcome showed a significant
 274 reduction in OARSI scores from 5 in the OA model to 1.75 after exosome treatment, indicating a
 275 substantial therapeutic effect. Lin et al. (2021) employed a single intra-articular injection of 100
 276 μ l human-derived exosomes in animals weighing approximately 358 ± 5 grams, reporting a
 277 primary outcome of a decrease in OARSI scores from 2.3 in the OA model to 1.25 post-
 278 treatment. Jin et al. (2021) used 50 μ l of human-derived exosomes at a concentration of $5 \times$
 279 10^{10} /ml, administered via intra-articular injections, with two doses given to 8-week-old animals
 280 weighing 200 ± 20 grams. The primary outcome recorded a reduction in OARSI scores from 5.8
 281 in the OA model to 2 after exosome treatment. Liu et al. (2022) applied two intra-articular
 282 injections of 100 μ l human-derived exosomes to 12-week-old animals weighing 250 ± 20 grams.
 283 This research demonstrated a primary outcome of a significant decrease in OARSI scores from
 284 20.5 in the OA model to 11.5 after treatment. Wang et al. (2021) conducted their study using 30
 285 μ l human-derived exosomes administered intra-articularly in two doses, though the age and
 286 weight of the animals were not specified. The OARSI scores were reduced from 21.2 in the OA
 287 model to 10.5 following treatment. Lastly, Tao et al. (2017) administered 100 μ l of human-
 288 derived exosomes via intra-articular injections in two doses to 12-week-old animals weighing
 289 between 300-350 grams. This study observed a decrease in OARSI scores from 22 in the OA
 290 model to 9.25 after exosome treatment.

291 **Table 3.** Dosage administration of human-derived exosome treatment for OA.

Author's Name	Dosage Administration		Administration Route	No. of dosage	Age (weeks)	Weight	OARSI Scores			Ref
	Control	Exosome Treatment					Control	OA Model	After Exosome Treatment	
Zhu. <i>et.al</i>	8 μ l	(1.0×10^{10} /ml)	Intra-articular	2	6	NG	0.3	5	1.75	(Zhu et al., 2017)
Lin. <i>et.al</i>	100 μ l	100 μ l	Intra-articular	1	NG	358 ± 5 g	0.25	2.3	1.25	(Lin et al.,

										2021)
Jin. <i>et.al</i>	50 µl	5 x 10 ¹⁰ /ml	Intra-articular	2	8	200±20g	4.3	5.8	2	(Jin et al., 2021)
Liu. <i>et.al</i>		100µl	Intra-articular	2	12	250±20g	0.25	20.5	11.5	(Y. Liu et al., 2022)
Wang. <i>et.al</i>	30µl	30µl	Intra-articular	2	NG	NG	0.25	21.2	10.5	(Wang et al., 2021)
Tao. <i>et.al</i>	100µl	100µl	Intra-articular	2	12	300-350g	0.2	22	9.25	(Tao et al., 2017)

292 Comparatively, animal-derived exosomes also exhibited therapeutic efficacy but with varying
 293 degrees of success (**Table 4**). For instance, Cosenza et al. (2017) observed a reduction in OARSI
 294 scores from 11 to 5.8, and Liang et al. (2020) reported a decrease from 12.5 to 7.54. These
 295 findings underscore the consistent and effective results of exosome treatments in reducing OA
 296 severity, with human-derived exosomes showing a slight edge due to more consistently effective
 297 outcomes across multiple studies. This highlights the promising potential of both human and
 298 animal-derived exosomes, emphasizing the need for further research to fully elucidate the
 299 therapeutic mechanisms and optimize the clinical application of exosome-based therapies in OA
 300 treatment.


301 **Table 4.** Dosage administration of animal-derived exosome treatment for OA.

Author's Name	Dosage units	Route of administration	No. of dosage	Age (weeks)	Weight	OARSI Scores			Ref
						Control	OA Model	After Exosome Treatment	
Cosenza. <i>et.al.</i>	200ng	Intra-articular	3	10	NG	1.5	11	5.8	(Cosenza et al., 2017)
Zhang. <i>et.al</i>	40µl	Intra-articular	1	NG	200-250g	0.8	3.1	1.5	(He et al., 2020)
He. <i>et.al</i>	40µg	Intra-articular	1	10	NG	1	4.1	3	(Liang et al., 2022)
Liang. <i>et.al.</i>	50 or 100ug	Intra-articular	1	6	NG	0.3	12.5	7.54	(J. Zhang et al., 2020)

302

303 *3.3. Analysis of Exosome Therapy Derived from Human and Animal Sources*

304 The finding presents a comprehensive analysis of the overall efficacy of exosome treatments on
 305 osteoarthritis (OA) across all included studies. This forest plot **Figure 2**, aggregates data from
 306 both human and animal-derived exosomes, providing a pooled estimate that reflects the general
 307 effectiveness of these therapies in managing OA. The pooled estimate indicates a significant
 308 positive effect of exosome therapy, with an odds ratio (OR) of 0.51 (95% CI: 0.41 to 0.61), and a
 309 p-value of less than 0.01, demonstrating the therapy's effectiveness in reducing OA severity.
 310 However, substantial heterogeneity is observed among the studies ($I^2 = 94\%$), suggesting



311 considerable variability in effect sizes. In the studies for human-derived exosomes, Zhu et al.
 312 (2017) reported an OR of 0.34 (95% CI: 0.21 to 0.49), contributing 8.9% to the overall weight.
 313 Tao et al. (2017) observed an OR of 0.52 (95% CI: 0.31 to 0.73), with a weight of 7.2%. Lin et
 314 al. (2020) reported an OR of 0.50 (95% CI: 0.31 to 0.69), contributing 7.8% to the weight. Jin et
 315 al. (2021) showed an OR of 0.50 (95% CI: 0.43 to 0.56), with a weight contribution of 10.2%.
 316 Wang et al. (2021) observed an OR of 0.56 (95% CI: 0.49 to 0.63), contributing 10.2% to the
 317 weight. Liu et al. (2022) reported an OR of 0.42 (95% CI: 0.35 to 0.49), with a weight
 318 contribution of 10.2%. Li et al. (2022) showed the highest OR of 0.88 (95% CI: 0.80 to 0.93),
 319 contributing 10.3% to the weight. Similarly, in the studies for animal-derived exosomes, Cosenza
 320 et al. (2017) reported an OR of 0.38 (95% CI: 0.21 to 0.58), contributing 7.9% to the overall
 321 weight. He et al. (2020) showed an OR of 0.34 (95% CI: 0.22 to 0.48), with a weight
 322 contribution of 9.1%. Zhang et al. (2019) reported an OR of 0.50 (95% CI: 0.41 to 0.59),
 323 contributing 9.8% to the weight. Liang et al. (2022) observed an OR of 0.62 (95% CI: 0.46 to
 324 0.77), contributing 8.5% to the weight.

325 **Figure 2.** The forest plot illustrates the efficacy rates of human and animal-derived exosomes *in*
326 *vivo* treatment of OA (**with their 95 % confidence intervals**).


327 Both human and animal-derived exosomes demonstrate substantial reductions in OA severity,
328 with human-derived exosomes showing a broader range of ORs from 0.34 (Zhu et al., 2017) to
329 0.88 (Li et al., 2022), indicating variability but consistently effective outcomes. In contrast,
330 animal-derived exosomes show ORs ranging from 0.34 (He et al., 2020) to 0.62 (Liang et al.,
331 2022), also indicating efficacy but with slightly less variability. Human-derived exosome studies
332 tend to have higher weight contributions (up to 10.3% for Li et al., 2022) compared to animal-
333 derived exosome studies, suggesting a greater overall influence on the meta-analysis outcomes.
334 This overview provides a crucial understanding of the broad impact of exosome-based therapies
335 on OA, offering a snapshot of the therapeutic potential of these treatments across diverse study
336 conditions.

337

338 *3.4. Assessment of Experimental Subjects and Osteoarthritis Models Utilized for Evaluating*
339 *Exosome Efficacy*

340 A detailed assessment of experimental subjects and osteoarthritis (OA) models was utilized in
341 various studies to evaluate the efficacy of exosome therapy. Each study is represented by a bar
342 that indicates the OA model employed and the type of experimental subject used. The OA
343 models include Anterior Cruciate Ligament Transection (ACL) combined with Medial
344 Meniscectomy (MM), Anterior Cruciate Ligament Transection (ACLT) combined with
345 Destabilization of the Medial Meniscus (DMM), Collagenase-induced OA, DMM alone, Medial
346 Collateral Ligament (MCL) combined with MM, Monosodium Iodoacetate (MIA)-induced OA,
347 and Osteochondral Defect. The experimental subjects are color-coded to distinguish between
348 Mice (C57BL/10), Mice (C57BL/6), New Zealand White Rabbits, and Rats (Sprague-Dawley).

349 The studies exhibit a diverse range of OA models and experimental subjects. For instance, Zhu et
350 al. (2017) used C57BL/10 mice in an ACL & MM model, while Zhang et al. (2020) utilized
351 C57BL/6 mice in a DMM model. Zhang et al. (2019) and Yang et al. (2022) both employed New
352 Zealand White Rabbits but used different OA models, specifically ACLT & DMM and DMM,
353 respectively. Studies by Wang et al. (2021) and He et al. (2020) used C57BL/6 mice in
354 Collagenase-induced and DMM models, respectively. The use of Sprague-Dawley rats is
355 common in several studies, such as Tao et al. (2017), Liu et al. (2022), Lin et al. (2020), Liang et
356 al. (2022), Li et al. (2022), Jin et al. (2021), and Cosenza et al. (2017). These studies employed a




357 variety of **Figure 3**. The heatmap illustrates the experimental subjects (on the right side) and
358 osteoarthritis (OA) models (along the x-axis) analyzed across all studies (on the left side of the y-
359 axis).

360 OA models including MIA-induced, Osteochondral Defect, and combinations of ligament
 361 transection and meniscectomy. This diversity in experimental design reflects the different
 362 approaches to modeling OA and evaluating exosome efficacy, with each model and subject type
 363 providing unique insights into the therapeutic potential of exosomes.

364 Overall, this highlights the diversity in experimental methodologies used across studies assessing
 365 exosome therapy for OA. This underlines the importance of considering both the OA model and
 366 the experimental subject when interpreting results and comparing outcomes across different
 367 research efforts.

368 3.5. Source Analysis of Exosomes from Human and Animal Mesenchymal Stem Cells

369 The forest plot analysis shown in **Figure 4** provides a more detailed analysis by categorizing the
 370 studies based on the source of the exosome's human versus animal. This subgroup analysis
 371 offers a nuanced understanding of how the efficacy of exosome treatments varies depending on
 372 their origin. Many of the included publications, whether employing human or animal sources of
 373 mesenchymal stem cells, support exosome-based treatment for osteoarthritis. The analysis
 374 indicates that exosomes derived from human sources show a slightly higher pooled effect size of
 375 0.53 [0.44; 0.63], compared to 0.44 [0.28; 0.60] for animal-derived exosomes, suggesting that




376 exosomes from human sources may have a marginally greater therapeutic impact on OA.

377 **Figure 4.** The forest plot displays the efficacy of exosomes derived from human and animal
 378 mesenchymal stem cells, as reported in the selected studies.

379 Moreover, exosomes generated from bone marrow have been particularly noted for their
 380 usefulness in the treatment of osteoarthritis, highlighting their potential not only in human
 381 applications but also for veterinary purposes. The heterogeneity within each subgroup ($I^2=94\%$
 382 for humans and $I^2=75\%$ for animals) emphasizes the variability in outcomes, with human-
 383 derived exosomes showing more inconsistency across studies. This detailed breakdown is
 384 essential for clinicians and researchers who are considering the source of exosomes in their
 385 therapeutic applications, as it provides insights into the relative efficacy and variability of human
 386 versus animal-derived treatments, with bone marrow-derived exosomes showing significant
 387 promise.

388 *3.6. Risk of bias in the eligible studies*

389 **Figure 5** provides a comprehensive risk of bias assessment for 13 included studies using the
 390 QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies 2), evaluating five key
 391 domains: randomization process (D1), timing of participant recruitment relative to randomization
 392 (D1b), deviations from intended intervention (D2), missing outcome data (D3), outcome
 393 measurement (D4), and selection of reported results (D5). The majority of studies exhibit a low
 394 risk of bias across most domains, particularly in D2, D3, D4, and D5, indicating that these
 395 aspects were generally well-controlled. However, several studies (e.g., Wang et al., 2021; Tao et



396 al., 2017)

397 **Figure 5.** Grouped bar charts illustrating the risk of bias across 13 included studies, were
398 assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies-2).

399 show a high risk of bias in D1, related to the randomization process, raising concerns about
400 internal validity. The D1b domain was not applicable in many cases, reflecting its irrelevance to
401 some study designs. Moderate concerns are noted in a few studies (e.g., Jin et al., 2021) in
402 specific domains, and some studies lack sufficient information to assess certain biases fully,
403 particularly in D1b and D1. Overall, while most studies maintain low to moderate risks of bias,
404 significant issues in the randomization process in some studies highlight the need for rigorous
405 study design and transparent reporting to ensure the reliability of findings in exosome-based
406 osteoarthritis treatments.

407 **4. Discussion**

408 In this study, we rigorously evaluated the efficacy of MSC-derived exosome therapy in
409 mitigating osteoarthritis symptoms in preclinical animal models, while systematically elucidating
410 the mechanisms underlying its therapeutic effects. Our focus on osteoarthritis is justified by its
411 status as the most prevalent degenerative disease, a leading cause of disability, and its strong
412 association with chronic pain and various joint abnormalities, including articular cartilage
413 damage, synovial inflammation, subchondral bone remodeling, and osteophyte formation
414 (Steinmetz et al., 2023; Tong et al., 2022).

415 We conducted a thorough analysis of 13 peer-reviewed studies published between 2016 and
416 2023, exploring the therapeutic potential of exosomes derived from both human and animal
417 sources. This analysis was designed to deepen our understanding of exosome therapy's impact on
418 osteoarthritis progression, accounting for critical factors such as administration methods, dosage
419 frequency, patient age, weight, and OARSI scores. Our findings unequivocally demonstrate
420 several key properties of exosomes, and the experimental models employed. Notably, exosomes,
421 typically ranging in size from 30 to 150 nm, are most effectively administered via the intra-
422 articular route. Despite the clear focus on human osteoarthritis in the literature, a glaring gap
423 persists in research on the application of exosome therapy in veterinary medicine. The reviewed
424 studies consistently show that exosomes significantly reduce the inflammatory response and
425 improve OARSI scores, a crucial measure of osteoarthritis severity encompassing factors like
426 physical function, stiffness, and pain. Remarkably, none of the studies reported adverse effects,
427 underscoring the promise of exosome therapy, particularly as it results in significant reductions
428 in OARSI scores in preclinical settings.

429 Exosomes play an essential role in modulating immune responses, addressing cardiovascular
430 disorders, combating degenerative diseases, and even influencing cancer progression. Their
431 multifaceted functions, including tissue repair, immune response modulation, and inflammation
432 reduction, position MSC-derived exosomes at the forefront of regenerative medicine (Zakirova et

433 al., 2020). Acting as intercellular messengers, exosomes transport biologically active
434 molecules—such as lipids, proteins, miRNAs, and multimolecular complexes—that are critical
435 in regulating homeostasis and metabolism (Colombo, Raposo, & Théry, 2014). These
436 characteristics make exosomes invaluable for both therapeutic and diagnostic applications, with
437 evidence suggesting that extracellular vesicles alone can effectively heal injuries and repair
438 tissue, thereby circumventing the practical challenges posed by stem cell-based protocols in
439 veterinary medicine (Diomaiuto et al., 2021).

440 The selection of appropriate animal models is indispensable in osteochondral defect and
441 osteoarthritis research. Our analysis identified the use of various animal models, including mice
442 (C57B/L10, C57B/L6), New Zealand White rabbits, and Sprague-Dawley rats, each offering
443 unique advantages—whether in understanding genetic responses, anatomical similarities to
444 humans, or robustness and availability. The efficacy of exosome therapy for osteoarthritis is
445 evident, irrespective of the MSC source, with exosomes derived from human and animal sources,
446 particularly bone marrow, showing substantial promise in alleviating osteoarthritis symptoms.
447 The forest plot analysis further strengthens the case for exosome-based therapy, with the
448 majority of studies yielding positive results.

449 Our analysis highlights a critical limitation: the paucity of veterinary models in the existing
450 literature. While research predominantly focuses on human osteoarthritis, there is a conspicuous
451 lack of studies investigating the use of exosomes in veterinary contexts. This gap limits the
452 generalizability of our findings to veterinary health, as the effectiveness of exosome therapy in
453 preclinical animal models may not fully capture the complexities of osteoarthritis in veterinary
454 patients. Additionally, the considerable variability in experimental methodologies, including
455 delivery routes, dosage frequencies, and assessment techniques, introduces potential
456 inconsistencies and complicates the establishment of standardized protocols for exosome therapy
457 in both human and veterinary medicine. The transition from preclinical models to clinical
458 applications presents significant challenges, given the inherent differences between animal
459 models and actual patients, whether human or veterinary, which may limit the direct applicability
460 of the findings.

461 Given these limitations, future research shifts must focus on exosome therapy in veterinary
462 patients with osteoarthritis. Comparative studies involving a broader range of species—such as
463 dogs, cats, and horses—are essential to fully assess the efficacy and safety of exosome therapy
464 across diverse veterinary populations. Incorporating organ-on-chip (OOC) technology into these
465 investigations is a crucial next step. OOC platforms offer unparalleled insights into the
466 mechanisms and therapeutic benefits of exosome therapy by accurately replicating physiological
467 conditions, enabling real-time monitoring of cellular responses, and facilitating sophisticated
468 disease modeling and high-throughput screening (Kang et al., 2021). This approach has the
469 potential to significantly enhance our understanding of exosome therapy's impact across different
470 species, thereby improving translational outcomes in veterinary medicine.

471 Furthermore, the standardization of experimental protocols—such as administration routes,
472 dosage regimens, and outcome measures—is critical for enhancing the comparability and
473 reproducibility of research findings. Establishing consensus guidelines for conducting preclinical
474 exosome therapy studies will strengthen the robustness and credibility of the research, paving the
475 way for more reliable conclusions. As we move from preclinical research to clinical applications,
476 well-designed clinical trials are essential to validate the safety and efficacy of exosome therapy
477 in osteoarthritis treatment for both human and veterinary patients. Such trials will provide
478 definitive evidence of the clinical utility of exosome therapy, laying the groundwork for its
479 broader adoption in medical practice.

480 **5. Conclusion**

481 In conclusion, our study unequivocally demonstrates the effectiveness of MSC-derived exosome
482 therapy in preclinical osteoarthritis models, underscoring the significant potential of exosome-
483 based interventions to alleviate osteoarthritis symptoms. Through a rigorous and systematic
484 analysis of existing literature, we have pinpointed critical factors that influence the success of
485 exosome therapy, including the source of mesenchymal stem cells, administration routes, and
486 experimental protocols. While our study acknowledges limitations, such as the
487 underrepresentation of veterinary models and variability in experimental designs, these do not
488 detract from the compelling evidence we present. Exosome therapy emerges as a promising and
489 innovative approach for treating osteoarthritis, poised to transform both human and veterinary
490 medicine. Moving forward, research efforts must intensify to resolve outstanding questions,
491 standardize protocols, and expedite the clinical application of exosome therapy. Our findings
492 contribute decisively to the growing body of evidence supporting the adoption of exosome
493 therapy in osteoarthritis treatment, with far-reaching implications for both public and veterinary
494 health.

495
496 **Declaration of Interests:** The authors declare that they have no competing interests.

497 **Ethics approval and consent to participate:** 'Not applicable'

498 **Consent for publication:** All authors have given their consent to publish

499 **Availability of data and materials:** The authors confirm that the data supporting the findings of
500 this study are available within the article.

501 **Competing interests:** None

502 **Funding:** VtR Inc-CGU (SCRPD1L0221); DOXABIO-CGU (SCRPD1K0131), and CGU grant
503 (UZRPD1L0011, UZRPD1M0081).

504 **Authors' contributions:** All authors have equally contributed to the conceptualization,
505 methodology, and writing and editing of the manuscript.

506 **Acknowledgements:** This research was funded by VtR Inc-CGU (SCRPD1L0221); DOXABIO-
507 CGU (SCRPD1K0131), and CGU grant (UZRPD1L0011, UZRPD1M0081). We have not used
508 AI in the preparation of the manuscript.

509

510

511

512

513

514 **References**

- 515 Alliance, O. O. A. OA PREVALENCE AND BURDEN. Retrieved from
516 <https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/>
- 517 Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular
518 interactions of exosomes and other extracellular vesicles. *Annual review of cell and*
519 *developmental biology*, 30, 255-289.
- 520 Cosenza, S., Ruiz, M., Toupet, K., Jorgensen, C., & Noël, D. (2017). Mesenchymal stem cells
521 derived exosomes and microparticles protect cartilage and bone from degradation in
522 osteoarthritis. *Scientific Reports*, 7(1), 16214. doi:10.1038/s41598-017-15376-8
- 523 Diomaiuto, E., Principe, V., De Luca, A., Laperuta, F., Alterisio, C., & Di Loria, A. (2021).
524 Exosomes in Dogs and Cats: An Innovative Approach to Neoplastic and Non-Neoplastic
525 Diseases. *Pharmaceuticals*, 14(8), 766. Retrieved from [https://www.mdpi.com/1424-](https://www.mdpi.com/1424-8247/14/8/766)
526 [8247/14/8/766](https://www.mdpi.com/1424-8247/14/8/766)
- 527 DuoGenicStemCellscorporation. (2023). Treating Osteoarthritis Without Surgery! Bring you
528 back to a lively life. Retrieved from [https://www.dgsc.com.tw/treat-osteoarthritis-](https://www.dgsc.com.tw/treat-osteoarthritis-without-surgery-freedom-of-movement-with-pcp-cell-therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20from%20joint%20pain)
529 [without-surgery-freedom-of-movement-with-pcp-cell-](https://www.dgsc.com.tw/treat-osteoarthritis-without-surgery-freedom-of-movement-with-pcp-cell-therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20from%20joint%20pain)
530 [therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20fr](https://www.dgsc.com.tw/treat-osteoarthritis-without-surgery-freedom-of-movement-with-pcp-cell-therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20from%20joint%20pain)
531 [om%20joint%20pain](https://www.dgsc.com.tw/treat-osteoarthritis-without-surgery-freedom-of-movement-with-pcp-cell-therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20from%20joint%20pain)
- 532 Economist, T. (2019) Spotlight on unmet needs in osteoarthritis; Global Burden of Disease Data
533 Retrieved from
534 [https://osteoarthritisineurope.eiu.com/infographic/#:~:text=In%202019%2C%20over%20](https://osteoarthritisineurope.eiu.com/infographic/#:~:text=In%202019%2C%20over%2057%20million,grown%20by%2054%25%20since%201990)
535 [57%20million,grown%20by%2054%25%20since%201990](https://osteoarthritisineurope.eiu.com/infographic/#:~:text=In%202019%2C%20over%2057%20million,grown%20by%2054%25%20since%201990)
- 536 Gangoda, L., Boukouris, S., Liem, M., Kalra, H., & Mathivanan, S. (2015). Extracellular vesicles
537 including exosomes are mediators of signal transduction: Are they protective or
538 pathogenic? *PROTEOMICS*, 15(2-3), 260-271.
539 doi:<https://doi.org/10.1002/pmic.201400234>
- 540 Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015). Exosomes and their
541 roles in immune regulation and cancer. *Seminars in Cell & Developmental Biology*, 40,
542 72-81. doi:<https://doi.org/10.1016/j.semcd.2015.02.009>
- 543 He, L., He, T., Xing, J., Zhou, Q., Fan, L., Liu, C., . . . Rong, L. (2020). Bone marrow
544 mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee
545 osteoarthritis pain in a rat model of osteoarthritis. *Stem Cell Research & Therapy*, 11(1),
546 276. doi:10.1186/s13287-020-01781-w
- 547 Himanshu, Mukherjee R, Vidic J, Leal E, da Costa AC, Prudencio CR, Raj VS, Chang CM,
548 Pandey RP. Nanobiotics and the One Health Approach: Boosting the Fight against
549 Antimicrobial Resistance at the Nanoscale. *Biomolecules*. 2023 Jul 28;13(8):1182.
- 550
- 551 Howitt, J., & Hill, A. F. (2016). Exosomes in the Pathology of Neurodegenerative Diseases*.
552 *Journal of Biological Chemistry*, 291(52), 26589-26597.
553 doi:<https://doi.org/10.1074/jbc.R116.757955>

- 554 Jin, Y., Xu, M., Zhu, H., Dong, C., Ji, J., Liu, Y., . . . Gu, Z. (2021). Therapeutic effects of bone
555 marrow mesenchymal stem cells-derived exosomes on osteoarthritis. *Journal of Cellular*
556 *and Molecular Medicine*, 25(19), 9281-9294. doi:<https://doi.org/10.1111/jcmm.16860>
- 557 Kang, Y., Niu, Z., Hadlock, T., Purcell, E. K., Lo, T., Zeinali, M., Owen, S., Keshamouni, V. G.,
558 Reddy, R. M., Ramnath, N., & Nagrath, S. (2021, January 28). On-Chip Biogenesis of
559 Circulating NK Cell-Derived Exosomes in Non-Small Cell Lung Cancer Exhibits
560 Antitumoral Activity. *Advanced Science*. <https://doi.org/10.1002/adv.202003747>
- 561 Li, S.-p., Lin, Z.-x., Jiang, X.-y., & Yu, X.-y. (2018). Exosomal cargo-loading and synthetic
562 exosome-mimics as potential therapeutic tools. *Acta Pharmacologica Sinica*, 39(4), 542-
563 551. doi:10.1038/aps.2017.178
- 564 Li, X., Wang, Y., Cai, Z., Zhou, Q., Li, L., & Fu, P. (2021). Exosomes from human umbilical
565 cord mesenchymal stem cells inhibit ROS production and cell apoptosis in human
566 articular chondrocytes via the miR-100-5p/NOX4 axis. *Cell Biology International*,
567 45(10), 2096-2106. doi:<https://doi.org/10.1002/cbin.11657>
- 568 Liang, Y., Xu, X., Xu, L., Iqbal, Z., Ouyang, K., Zhang, H., . . . Xia, J. (2022). Chondrocyte-
569 specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment.
570 *Theranostics*, 12(11), 4866-4878. doi:10.7150/thno.69368
- 571 Liberati, A., Altman, D., Tetzlaff, J., & Mulrow, C. (2009). Gøtzsche PC, Ioannidis JP, et al. The
572 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
573 evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*, 62(10),
574 e1-34.
- 575 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., . . . Moher,
576 D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of
577 studies that evaluate health care interventions: explanation and elaboration. *J Clin*
578 *Epidemiol*, 62(10), e1-34. doi:10.1016/j.jclinepi.2009.06.006
- 579 Lin, T., Wu, N., Wang, L., Zhang, R., Pan, R., & Chen, Y.-F. (2021). Inhibition of chondrocyte
580 apoptosis in a rat model of osteoarthritis by exosomes derived from
581 miR-140-5p-overexpressing human dental pulp stem cells. *Int J Mol Med*, 47(3), 7.
582 doi:10.3892/ijmm.2020.4840
- 583 Liu, W., Bai, X., Zhang, A., Huang, J., Xu, S., & Zhang, J. (2019). Role of Exosomes in Central
584 Nervous System Diseases. *Frontiers in Molecular Neuroscience*, 12.
585 doi:10.3389/fnmol.2019.00240
- 586 Liu, Y., Zeng, Y., Si, H. B., Tang, L., Xie, H. Q., & Shen, B. (2022). Exosomes Derived From
587 Human Urine-Derived Stem Cells Overexpressing miR-140-5p Alleviate Knee
588 Osteoarthritis Through Downregulation of VEGFA in a Rat Model. *Am J Sports Med*,
589 50(4), 1088-1105. doi:10.1177/03635465221073991
- 590 Papazova, D. A., Oosterhuis, N. R., Gremmels, H., Van Koppen, A., Joles, J. A., & Verhaar, M.
591 C. (2015). Cell-based therapies for experimental chronic kidney disease: a systematic
592 review and meta-analysis. *Disease models & mechanisms*, 8(3), 281-293.
- 593 Pandey RP, Mukherjee R, Chang CM. Emerging Concern with Imminent Therapeutic Strategies
594 for Treating Resistance in Biofilm. *Antibiotics (Basel)*. 2022 Apr 2;11(4):476.
- 595
- 596
- 597 Pandey RP, Mukherjee R, Priyadarshini A, Gupta A, Vibhuti A, Leal E, Sengupta U, Katoch
598 VM, Sharma P, Moore CE, Raj VS, Lyu X. Potential of nanoparticles encapsulated drugs

- 599 for possible inhibition of the antimicrobial resistance development. *Biomed*
600 *Pharmacother.* 2021 Sep;141:111943.
- 601 Pandey RP, Mukherjee R, Chang CM. Antimicrobial resistance surveillance system mapping in
602 different countries. *Drug Target Insights.* 2022 Nov 30;16:36-48.
- 603 PFMA, P. P. (2018). APPA National Pet Owners Survey. Retrieved from
604 <https://www.pfma.org.uk/pet-population-2018>
- 605 SA, J. (1997). Osteoarthritis. Joint anatomy, physiology, and pathobiology. *Vet Clin North Am*
606 *Small Anim Pract.*, 27, 699–723. doi:10.1016/S0195-5616(97)50076-3
- 607 Singh, A., Das, S., Chopra, A., Danda, D., Paul, B. J., March, L., . . . Antony, B. (2022). Burden
608 of osteoarthritis in India and its states, 1990–2019: findings from the Global Burden of
609 disease study 2019. *Osteoarthritis and Cartilage*, 30(8), 1070-1078.
610 doi:<https://doi.org/10.1016/j.joca.2022.05.004>
- 611 Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R,
612 Maiti TK, Johri AK, Tiwari A, Pandey AK, Awasthi A. Gefitinib Results in Robust Host-
613 Directed Immunity Against *Salmonella* Infection Through Proteo-Metabolomic
614 Reprogramming. *Front Immunol.* 2021 Mar 31;12:648710.
- 615 Smith, V. L., Cheng, Y., Bryant, B. R., & Schorey, J. S. (2017). Exosomes function in antigen
616 presentation during an in vivo *Mycobacterium tuberculosis* infection. *Scientific Reports*,
617 7(1), 43578. doi:10.1038/srep43578
- 618 Steinmetz, J. D., Culbreth, G. T., Haile, L. M., Rafferty, Q., Lo, J., Fukutaki, K. G., . . . Kopec, J.
619 A. (2023). Global, regional, and national burden of osteoarthritis, 1990–2020 and
620 projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
621 *The Lancet Rheumatology*, 5(9), e508-e522. doi:[https://doi.org/10.1016/S2665-](https://doi.org/10.1016/S2665-9913(23)00163-7)
622 [9913\(23\)00163-7](https://doi.org/10.1016/S2665-9913(23)00163-7)
- 623 Sterne JAC, S. J., Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett
624 MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P,
625 Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart
626 LA, Tilling K, White IR, Whiting PF, Higgins JPT. (2019). RoB 2: a revised tool for
627 assessing risk of bias in randomised trials. . *BMJ* (366), 14898.
628 doi:<https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool?authuser=0>
- 629 Sun, A. R., Udduttula, A., Li, J., Liu, Y., Ren, P.-G., & Zhang, P. (2021). Cartilage tissue
630 engineering for obesity-induced osteoarthritis: Physiology, challenges, and future
631 prospects. *Journal of Orthopaedic Translation*, 26, 3-15.
632 doi:<https://doi.org/10.1016/j.jot.2020.07.004>
- 633 Suresh K, Mahendra PS, Vijay kB, et al. Quality control of vaccines-A journey from classical
634 approach to 3Rs. *Microbiol Curr Res.* 2018;2(2):14-30.
- 635 Sun, X., Zhen, X., Hu, X., Li, Y., Gu, S., Gu, Y., & Dong, H. (2019). Osteoarthritis in the
636 Middle-Aged and Elderly in China: Prevalence and Influencing Factors. *International*
637 *Journal of Environmental Research and Public Health*, 16(23), 4701. Retrieved from
638 <https://www.mdpi.com/1660-4601/16/23/4701>
- 639 Tao, S.-C., Yuan, T., Zhang, Y.-L., Yin, W.-J., Guo, S.-C., & Zhang, C.-Q. (2017). Exosomes
640 derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells
641 enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model.
642 *Theranostics*, 7(1), 180-195. doi:10.7150/thno.17133

- 643 Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., . . . Chen, D. (2022). Current
644 understanding of osteoarthritis pathogenesis and relevant new approaches. *Bone*
645 *Research*, 10(1), 60. doi:10.1038/s41413-022-00226-9
- 646 Wang, Z., Yan, K., Ge, G., Zhang, D., Bai, J., Guo, X., . . . Geng, D. (2021). Exosomes derived
647 from miR-155-5p–overexpressing synovial mesenchymal stem cells prevent osteoarthritis
648 via enhancing proliferation and migration, attenuating apoptosis, and modulating
649 extracellular matrix secretion in chondrocytes. *Cell Biology and Toxicology*, 37(1), 85-
650 96. doi:10.1007/s10565-020-09559-9
- 651 Wen, C., & Xiao, G. (2022). Advances in osteoarthritis research in 2021 and beyond. *Journal of*
652 *Orthopaedic Translation*, 32, A1-A2. doi:<https://doi.org/10.1016/j.jot.2022.02.011>
- 653 Wever, K. E., Menting, T. P., Rovers, M., van der Vliet, J. A., Rongen, G. A., Masereeuw, R., . .
654 . Warlé, M. (2012). Ischemic preconditioning in the animal kidney, a systematic review
655 and meta-analysis. *PloS one*, 7(2), e32296.
- 656 WHO. WHO's work on the UN Decade of Healthy Ageing (2021–2030). Retrieved from
657 <https://www.who.int/initiatives/decade-of-healthy-ageing>
- 658 WHO. (2023). Osteoarthritis. Retrieved from [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/osteoarthritis)
659 [sheets/detail/osteoarthritis](https://www.who.int/news-room/fact-sheets/detail/osteoarthritis)
- 660 Wu, J., Kuang, L., Chen, C., Yang, J., Zeng, W.-N., Li, T., . . . Yang, L. (2019). miR-100-5p-
661 abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage
662 and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. *Biomaterials*,
663 206, 87-100. doi:<https://doi.org/10.1016/j.biomaterials.2019.03.022>
- 664 Wu, X., Lai, Y., Chen, S., Zhou, C., Tao, C., Fu, X., . . . Xiao, G. (2022). Kindlin-2 preserves
665 integrity of the articular cartilage to protect against osteoarthritis. *Nature Aging*, 2(4),
666 332-347. doi:10.1038/s43587-021-00165-w
- 667 Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G.
668 (2023, February 3). *Osteoarthritis: pathogenic signaling pathways and therapeutic*
669 *targets*. Signal Transduction and Targeted Therapy. [https://doi.org/10.1038/s41392-023-](https://doi.org/10.1038/s41392-023-01330-w)
670 [01330-w](https://doi.org/10.1038/s41392-023-01330-w)
- 671 Zakirova, E. Y., Aimaletdinov, A. M., Malanyeva, A. G., Rutland, C. S., & Rizvanov, A. A.
672 (2020). Extracellular Vesicles: New Perspectives of Regenerative and Reproductive
673 Veterinary Medicine. *Frontiers in Veterinary Science*, 7. doi:10.3389/fvets.2020.594044
- 674 Zhang, J., Rong, Y., Luo, C., & Cui, W. (2020). Bone marrow mesenchymal stem cell-derived
675 exosomes prevent osteoarthritis by regulating synovial macrophage polarization. *Aging*
676 *(Albany NY)*, 12(24), 25138-25152. doi:10.18632/aging.104110
- 677 Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019). Exosomes: biogenesis, biologic function and
678 clinical potential. *Cell & Bioscience*, 9(1), 19. doi:10.1186/s13578-019-0282-2
- 679 Zhu, Y., Wang, Y., Zhao, B., Niu, X., Hu, B., Li, Q., . . . Wang, Y. (2017). Comparison of
680 exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and
681 synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis.
682 *Stem Cell Research & Therapy*, 8(1), 64. doi:10.1186/s13287-017-0510-9
683